Dubai: – Hikma Pharmaceuticals PLC [Hikma], the multinational pharmaceutical company, today announced plans to launch a new product for the treatment of asthma in adults and adolescents in the UAE. Asthma, a chronic respiratory disease, causes airways to be inflamed and narrowed making it difficult for patients to breathe. In the UAE, an estimated 1.3 million residents - around 14 per cent of the population - suffer from the condition.
The new treatment will be unveiled at a launch symposium to be organised by Hikma on Friday, 1 October, in the presence of Dr. Bassam Mahboub, Consultant Pulmonologist & Head of Pulmonary Medicine, Dubai Health Authority. Aligned with Hikma’s mission to play an important role in supporting educational medical programs, the symposium will help raise awareness on asthma and the treatments available.
To facilitate the sharing of medical knowledge among healthcare professionals, the symposium will include other speakers such as Professor Ashraf Alzaabi, MB FRCPC FCCP EMHCA, Head of Respiratory Division at Zayed Military Hospital in Abu Dhabi, and Professor Federico Lavorini, Professor of Respiratory Medicine at the Department of Clinical and Experimental Medicine, University of Florence Italy.
In his comments, Mohammad Sammour, Country Manager – Hikma UAE, said: “Hikma is looking forward to another milestone in the UAE, allowing us to expand our treatment portfolio. Studies show that as many as half of the country’s asthma patients have an emergency care visit at some point during the year.
He added, “Aligning with our mission to bring quality treatments across the region, we are confident that this new product will make our patients’ lives better.”
(LSE: HIK) (NASDAQ Dubai: HIK) (OTC: HKMPY) (rated BBB-/stable S&P, BBB-/stable Fitch and Ba1/stable Moody's)
Hikma helps put better health within reach every day for millions of people in more than 50 countries around the world. For more than 40 years, we've been creating high-quality medicines and making them accessible to the people who need them. Headquartered in the UK, we are a global company with a local presence across the United States (US), the Middle East and North Africa (MENA) and Europe, and we use our unique insight and expertise to transform cutting-edge science into innovative solutions that transform people's lives. We're committed to our customers, and the people they care for, and by thinking creatively and acting practically, we provide them with a broad range of branded and non-branded generic medicines. Together, our 8,600 colleagues are helping to shape a healthier world that enriches all our communities. We are a leading licensing partner, and through our venture capital arm, are helping bring innovative health technologies to people around the world. For more information, please visit: www.hikma.com
Hikma Pharmaceuticals PLC
+962 6 580 2900
© Press Release 2021
Disclaimer: The contents of this press release was provided from an external third party provider. This website is not responsible for, and does not control, such external content. This content is provided on an “as is” and “as available” basis and has not been edited in any way. Neither this website nor our affiliates guarantee the accuracy of or endorse the views or opinions expressed in this press release.
The press release is provided for informational purposes only. The content does not provide tax, legal or investment advice or opinion regarding the suitability, value or profitability of any particular security, portfolio or investment strategy. Neither this website nor our affiliates shall be liable for any errors or inaccuracies in the content, or for any actions taken by you in reliance thereon. You expressly agree that your use of the information within this article is at your sole risk.
To the fullest extent permitted by applicable law, this website, its parent company, its subsidiaries, its affiliates and the respective shareholders, directors, officers, employees, agents, advertisers, content providers and licensors will not be liable (jointly or severally) to you for any direct, indirect, consequential, special, incidental, punitive or exemplary damages, including without limitation, lost profits, lost savings and lost revenues, whether in negligence, tort, contract or any other theory of liability, even if the parties have been advised of the possibility or could have foreseen any such damages.